europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

Clinical Trials and Coronavirus

30/04/2020
BLOG
Clinical Trials and Coronavirus

<Clinical Trials and Coronavirus

Check out the latest news on coronavirus clinical trials.

In a true show of European solidarity in the fight against COVID-19, a French coordinated pan-European clinical trial began this week.

Called 'Discovery', the trial is led by Dr. Florence Ader, an infectious disease specialist in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital in Lyon. The WHO announced a global clinical trial last week - 'Solidarity', which will focus on a select number of medicines in fighting COVID-19: remdesivir, lopinavir and ritonavir, and chloroquine and hydroxychloroquine.

Discovery is a complimentary add-on clinical trial to Solidarity conducted at the European level and coordinated by INSERM, the French National Institute of Health and Medical Research. While the French aspect of the study will be funded by the Ministries of Higher Education, Research and Innovation, the European parts are funded by the public-private partnerships COMBACTE, PREPARE, and the EU-funded project RECOVER.

In France, some 800 patients will take part in the Discovery trial, while 3200 patients in total will be recruited from across Spain, Germany, the Benelux, and the United Kingdom – not even Brexit can stand in the way of European solidarity in the current climate.

Guidance on conducting clinical trials was released last week offering advice on how to deal with extraordinary situations which the coronavirus pandemic presents, as well as specific advice on trials for COVID-19 treatments. The guidance is available here.

EuropaBio and our members remain committed to aiding the fight against COVID-19. Only by working together will we succeed.

Sources:
• https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
• https://www.aa.com.tr/en/europe/clinical-trial-starts-in-france-for-treating-covid-19/1775935
• https://presse.inserm.fr/lancement-dun-essai-clinique-europeen-contre-le-covid-19/38737/
• https://www.raps.org/news-and-articles/news-articles/2020/3/ema-offers-guidance-on-conducting-trials-during-th

Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more
19/12/2022

The Association of Biotechnological Companies Bioforum joins EuropaBio: representing Polish biotech at European legislative fora and involving Polish companies in the debate about the future of the industry


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member